Corcept Therapeutics (CORT) Tops Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 --0%
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $123.6 million versus the consensus estimate of $119.71 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- United Community Banks completes balance sheet repositioning, expands buyback
- AEVEX acquires BlackSea Technologies, expanding into maritime drones
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
